Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal dissemination-Reference-Cited by-同舟云学术

Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal dissemination

Published:2010-06-08 Issue:6 Volume:29 Page:1198-1205
ISSN:0167-6997
Container-title:Investigational New Drugs
language:en
Short-container-title:Invest New Drugs

Author:

Taguchi Fumiko,Kodera Yasuo,Katanasaka Yasufumi,Yanagihara Kazuyoshi,Tamura Tomohide,Koizumi Fumiaki

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10637-010-9464-9.pdf

Reference32 articles.

1. Ohtsu A, Shimada Y, Shirao K, Boku N, Hyodo I, Saito H, Yamamichi N, Miyata Y, Ikeda N, Yamamoto S, Fukuda H, Yoshida S (2003) Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205). J Clin Oncol 21:54–59

2. Vanhoefer U, Rougier P, Wilke H, Ducreux MP, Lacave AJ, Van Cutsem E, Planker M, Santos JG, Piedbois P, Paillot B, Bodenstein H, Schmoll HJ, Bleiberg H, Nordlinger B, Couvreur ML, Baron B, Wils JA (2000) Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group. J Clin Oncol 18:2648–2657

3. Gunderson LL, Sosin H (1982) Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy. Int J Radiat Oncol Biol Phys 8:1–11

4. Hartgrink HH, van de Velde CJ, Putter H, Bonenkamp JJ, Klein Kranenbarg E, Songun I, Welvaart K, van Krieken JH, Meijer S, Plukker JT, van Elk PJ, Obertop H, Gouma DJ, van Lanschot JJ, Taat CW, de Graaf PW, von Meyenfeldt MF, Tilanus H, Sasako M (2004) Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial. J Clin Oncol 22:2069–2077

5. Yamada E, Miyaishi S, Nakazato H, Kato K, Kito T, Takagi H, Yasue M, Kato T, Morimoto T, Yamauchi M (1980) The surgical treatment of cancer of the stomach. Int Surg 65:387–399

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synergistic anticancer effects of everolimus (RAD001) and Rhein on gastric cancer cells via phosphoinositide-3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway;Bioengineered;2022-02-28

2. Targeted Molecular Therapies in the Treatment of Esophageal Adenocarcinoma, Are We There Yet?;Cancers;2020-10-22

3. MEK inhibition overcomes everolimus resistance in gastric cancer;Cancer Chemotherapy and Pharmacology;2020-05-22

4. mTOR signalling: jack-of-all-trades;Biochemistry and Cell Biology;2019-02

5. Everolimus;Recent Results in Cancer Research;2018